Skip to main content
Clinical Trials/NL-OMON38607
NL-OMON38607
Completed
Not Applicable

A pilot study on efficacy and safety of 100 ug start dose wasp venom immunotherapy (VIT) - EVVIT100

niversitair Medisch Centrum Groningen0 sites20 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
niversitair Medisch Centrum Groningen
Enrollment
20
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- A positive history of a systemic response grade II/III/IVa after vespid sting
  • \- Specific serum IgE \> 0\.7 kU/
  • \- Positive intracutaneous skin test for vespid venom ( at \<\= 1 µg/ml)

Exclusion Criteria

  • \- A positive history of a systemic response grade IVb according to Müller after a vespid sting
  • \- Age under 18 years or above 65 years
  • \- Severe cardiopulmonary disease (clinical evidence of congestive heart failure, coronary disease or severe hypertension)
  • \- Insufficiently controlled asthma, especially if FEV1 is 70% of predicted.
  • \- Conditions that influence the immune system (immune deficiencies, malignancy, auto\-immune diseases)
  • \- Severe kidney failure
  • \- Interfering medication with the outcome or recovery from a systemic reaction (β\-blockers and immunosuppressive drugs)
  • \- Allergy to auxiliary matter in Pharmalgen® Vespula spp.
  • \- Pregnancy
  • \- Mastocytosis

Outcomes

Primary Outcomes

Not specified

Similar Trials